Megan Garlapow, PhD

Contributing Writer https://www.cancertherapyadvisor.com

Megan Garlapow, PhD, is the principal and owner of The Line Medical Communications, LLC. Garlapow has worked across a wide variety of projects and therapeutic areas. She holds a BA in biology from the University of Chicago and a PhD in genetics from North Carolina State University. Before working as a medical writer, Garlapow worked in a biopsychology lab, examining social factors affecting breast cancer in rats and people and in a neurogenetics lab, examining the circadian factors affecting nicotine addiction in a mouse model. In her PhD, she used quantitative genetics approaches to examine the regulation of feeding. Her postdoctoral research at Arizona State University focused on environmental and genetic factors affecting body weight. You can find her on LinkedIn at https://www.linkedin.com/in/megangarlapow/

All articles by Megan Garlapow, PhD

Multiple Myeloma

No Correlation Between SF3B1 Mutation in Myelodysplastic Syndrome and Overall Survival

Megan Garlapow, PhD

April 22, 2019

Researchers evaluated 15 studies in patients with myelodysplastic syndrome to determine the prognostic value of mutations in the SF3B1 gene.

Lymphoma

Presence of Autoimmune Diseases May Increase Risk for Diffuse Large B Cell, Marginal Zone Lymphomas

Megan Garlapow, PhD

April 16, 2019

The presence of rheumatologic conditions was also associated with variations in cancer site for both diffuse large B-cell lymphoma and marginal zone lymphoma.

Needs-assessment survey identifies knowledge gaps of novel therapeutics for CACS

General Oncology

Addressing the Need for Palliative Care Integration Into Phase 1 Clinical Trials

Megan Garlapow, PhD

April 16, 2019

Researchers argue that palliative care integration into treatment regimens contribute to improving the quality of life for patients in phase 1 clinical trials.

Hematologic Cancers

Standardization of Minimal Residual Disease Measurements in Philadelphia-Positive ALL

Megan Garlapow, PhD

April 11, 2019

Variability in minimal residual disease measurement techniques inhibits the ability to compare data across laboratories and clinical trials.

Both the chemotherapy regimen selected and therapeutic dose intensity used in treatment factor into

Hematologic Cancers

Infections in Primary Immune Thrombocytopenia Associated With Low Platelet Count

Megan Garlapow, PhD

October 23, 2018

A retrospective study of platelet- and infection-related data from patients with ITP revealed the influence platelet levels have on infections as well as efficacy of transfusions.

Ulka Vaishampayan, MD, and Neeraj Agarwal, MD, spoke with Cancer Therapy Advisor about treatment rec

Renal Cell Carcinoma

Advanced Renal Cell Carcinoma: Interviews With Neeraj Agarwal, MD, and Ulka Vaishampayan, MD

Megan Garlapow, PhD

June 8, 2017

Ulka Vaishampayan, MD, and Neeraj Agarwal, MD, spoke with Cancer Therapy Advisor about treatment recommendations for patients newly diagnosed with metastatic RCC.

Dual expression of MYC and BCL2 was associated with worse survival among patients with GCB-like DLBC

Lymphoma

Poorer DLBCL Survival Outcomes Linked to Dual Expression of MYC, BCL2

Megan Garlapow, PhD

June 5, 2017

Dual expression of MYC and BCL2 was associated with worse survival among patients with GCB-like DLBCL, though this status was not associated with any outcomes among patients with ABC-like DLBCL.